{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:18:01Z","timestamp":1788207481112,"version":"build-2803163510"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00705-022-05365-2","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:03:12Z","timestamp":1643349792000},"page":"327-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The ins and outs of SARS-CoV-2 variants of concern (VOCs)"],"prefix":"10.1007","volume":"167","author":[{"given":"Mostafa","family":"Salehi-Vaziri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Fazlalipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahmood","family":"Seyed Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Pouriayevali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmineh","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabihollah","family":"Shoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-3052","authenticated-orcid":false,"given":"Ali","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"5365_CR1","unstructured":"WHO. COVID-19 weekly epidemiological update, 27 July 2021. 2021."},{"issue":"6","key":"5365_CR2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/pathogens9060426","volume":"9","author":"SN Neerukonda","year":"2020","unstructured":"Neerukonda SN, Katneni U (2020) A review on SARS-CoV-2 virology, pathophysiology, animal models, and anti-viral interventions. Pathogens 9(6):426","journal-title":"Pathogens"},{"issue":"2","key":"5365_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2005.02.017","volume":"335","author":"A Cheng","year":"2005","unstructured":"Cheng A, Zhang W, Xie Y, Jiang W, Arnold E, Sarafianos SG et al (2005) Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology 335(2):165\u2013176","journal-title":"Virology"},{"issue":"2","key":"5365_CR4","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","volume":"115","author":"F Ferron","year":"2018","unstructured":"Ferron F, Subissi L, Silveira De Morais AT, Le NTT, Sevajol M, Gluais L et al (2018) Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci 115(2):E162\u2013E171","journal-title":"Proc Natl Acad Sci"},{"key":"5365_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1073\/pnas.2024815118","volume":"118","author":"R Sender","year":"2021","unstructured":"Sender R, Bar-On YM, Gleizer S, Bernshtein B, Flamholz A, Phillips R et al (2021) The total number and mass of SARS-CoV-2 virions. Proc Natl Acad Sci 118:25","journal-title":"Proc Natl Acad Sci"},{"key":"5365_CR6","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; (April 21, 2020). Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"issue":"4","key":"5365_CR7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/microorganisms9040868","volume":"9","author":"M Maurin","year":"2021","unstructured":"Maurin M, Fenollar F, Mediannikov O, Davoust B, Devaux C, Raoult D (2021) Current status of putative animal sources of SARS-CoV-2 infection in humans: wildlife, domestic animals and pets. Microorganisms. 9(4):868","journal-title":"Microorganisms."},{"key":"5365_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.03.008","author":"JL Boechat","year":"2021","unstructured":"Boechat JL, Chora I, Morais A, Delgado L (2021) The immune response to SARS-CoV-2 and COVID-19 immunopathology\u2013current perspectives. Pulmonology. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.03.008","journal-title":"Pulmonology"},{"key":"5365_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2231","author":"D Focosi","year":"2021","unstructured":"Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. https:\/\/doi.org\/10.1002\/rmv.2231","journal-title":"Rev Med Virol"},{"issue":"13","key":"5365_CR10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2021.2088","volume":"325","author":"JR Mascola","year":"2021","unstructured":"Mascola JR, Graham BS, Fauci AS (2021) SARS-CoV-2 viral variants\u2014tackling a moving target. JAMA 325(13):1261\u20131262","journal-title":"JAMA"},{"key":"5365_CR11","unstructured":"SARS-CoV-2 Variant Classifications and Definitions23 Sep 2021. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html#Consequence."},{"key":"5365_CR12","unstructured":"Andrew Rambaut NL, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations2020. Available from: https:\/\/virological.org\/t\/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations\/563."},{"key":"5365_CR13","doi-asserted-by":"publisher","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv https:\/\/doi.org\/10.1101\/2020.12.21.20248640","DOI":"10.1101\/2020.12.21.20248640"},{"key":"5365_CR14","unstructured":"Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. Virological org Available at: https:\/\/virological.org\/t\/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein\/585. 2021."},{"key":"5365_CR15","unstructured":"B.1.617 variant first identified in India classified as variant of global concern [press release]. ctvnews.ca, 2021"},{"key":"5365_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.025","author":"X Deng","year":"2021","unstructured":"Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK et al (2021) Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.04.025","journal-title":"Cell"},{"key":"5365_CR17","doi-asserted-by":"publisher","unstructured":"Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Burglin L, Klapper P, et al (2021) Epidemiological investigation of new SARS-CoV-2 variant of concern 202012\/01 in England. medRxiv https:\/\/doi.org\/10.1101\/2021.01.14.21249386","DOI":"10.1101\/2021.01.14.21249386"},{"issue":"7858","key":"5365_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S, et al (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593(7858):270\u20134","journal-title":"Nature"},{"key":"5365_CR19","doi-asserted-by":"publisher","unstructured":"Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al (2021) Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data. medRxiv. https:\/\/doi.org\/10.1101\/2020.12.30.20249034","DOI":"10.1101\/2020.12.30.20249034"},{"key":"5365_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00055-4","author":"MS Graham","year":"2021","unstructured":"Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T et al (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study. Lancet Public Health. https:\/\/doi.org\/10.1016\/S2468-2667(21)00055-4","journal-title":"Lancet Public Health"},{"key":"5365_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n288","author":"E Mahase","year":"2021","unstructured":"Mahase E (2021) Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant. BMJ. https:\/\/doi.org\/10.1136\/bmj.n288","journal-title":"BMJ"},{"key":"5365_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.14.431117","author":"F Tian","year":"2021","unstructured":"Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z et al (2021) Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2. BioRxiv. https:\/\/doi.org\/10.1101\/2021.02.14.431117","journal-title":"BioRxiv"},{"key":"5365_CR23","doi-asserted-by":"publisher","unstructured":"Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, et al (2021) Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv https:\/\/doi.org\/10.1101\/2021.02.05.430003","DOI":"10.1101\/2021.02.05.430003"},{"issue":"3","key":"5365_CR24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41587-021-00845-3","volume":"39","author":"CA Ascoli","year":"2021","unstructured":"Ascoli CA (2021) Could mutations of SARS-CoV-2 suppress diagnostic detection? Nat Biotechnol 39(3):274\u2013275","journal-title":"Nat Biotechnol"},{"key":"5365_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n359","author":"J Wise","year":"2021","unstructured":"Wise J (2021) Covid-19: The E484K mutation and the risks it poses. BMJ. https:\/\/doi.org\/10.1136\/bmj.n359","journal-title":"BMJ"},{"issue":"2","key":"5365_CR26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/v13020146","volume":"13","author":"L Makowski","year":"2021","unstructured":"Makowski L, Olson-Sidford W, Weisel J (2021) Biological and clinical consequences of integrin binding via a rogue RGD motif in the SARS CoV-2 spike protein. Viruses 13(2):146","journal-title":"Viruses"},{"issue":"3","key":"5365_CR27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15585\/mmwr.mm7003e2","volume":"70","author":"SE Galloway","year":"2021","unstructured":"Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A et al (2021) Emergence of SARS-CoV-2 b. 1.1. 7 lineage\u2014united states, December 29, 2020\u2013January 12, 2021. Morbid Mortal Week Rep 70(3):95","journal-title":"Morbid Mortal Week Rep"},{"key":"5365_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2021.02.080","volume":"550","author":"F Pereira","year":"2021","unstructured":"Pereira F (2021) SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochem Biophys Res Commun 550:8\u201314","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"5365_CR29","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/jmv.26823","volume":"93","author":"JD Ram\u00edrez","year":"2021","unstructured":"Ram\u00edrez JD, Mu\u00f1oz M, Pati\u00f1o LH, Ballesteros N, Paniz-Mondolfi A (2021) Will the emergent SARS-CoV2 B. 1.1. 7 lineage affect molecular diagnosis of COVID-19? J Med Virol 93(5):2566\u20132568","journal-title":"J Med Virol"},{"issue":"7854","key":"5365_CR30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J et al (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592(7854):438\u2013443","journal-title":"Nature"},{"key":"5365_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijid.2020.06.027","volume":"97","author":"L Pe\u00f1arrubia","year":"2020","unstructured":"Pe\u00f1arrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Manissero D et al (2020) Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis 97:225\u2013229","journal-title":"Int J Infect Dis"},{"issue":"9","key":"5365_CR32","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM et al (2021) Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. Cell. 184(9):2348-23461.e6","journal-title":"Cell."},{"key":"5365_CR33","doi-asserted-by":"publisher","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv https:\/\/doi.org\/10.1101\/2020.12.21.20248640","DOI":"10.1101\/2020.12.21.20248640"},{"issue":"7857","key":"5365_CR34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y et al (2021) Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 593(7857):130\u2013135","journal-title":"Nature."},{"issue":"6544","key":"5365_CR35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","volume":"372","author":"NR Faria","year":"2021","unstructured":"Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S et al (2021) Genomics and epidemiology of the P 1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372(6544):815\u2013821","journal-title":"Science"},{"key":"5365_CR36","doi-asserted-by":"publisher","unstructured":"Freitas AR, Lemos DR, Beckedorff OA, Cavalcante LP, Siqueira AM, Mello RC, et al. (2021) The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P. 1 was greater among young adults without pre-existing risk conditions. medRxiv https:\/\/doi.org\/10.1101\/2021.04.13.21255281","DOI":"10.1101\/2021.04.13.21255281"},{"issue":"6544","key":"5365_CR37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","volume":"372","author":"NR Faria","year":"2021","unstructured":"Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al (2021) Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372(6544):815\u201321","journal-title":"Science"},{"issue":"6","key":"5365_CR38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2021.03.013","volume":"82","author":"Y Hirotsu","year":"2021","unstructured":"Hirotsu Y, Omata M (2021) Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T\/E484K\/N501Y mutations in Kofu, Japan. J Infect. 82(6):276\u2013316","journal-title":"J Infect"},{"issue":"5","key":"5365_CR39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","volume":"29","author":"P Wang","year":"2021","unstructured":"Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G et al (2021) Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 29(5):747\u2013751","journal-title":"Cell Host Microbe."},{"key":"5365_CR40","doi-asserted-by":"publisher","unstructured":"Lamarca AP, de Almeida LG, da Silva Francisco R, Lima LFA, Scortecci KC, Perez VP, et al. (2021) Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P. 1 lineage and diversification within P. 2 clade in Brazil. medRxiv. https:\/\/doi.org\/10.1101\/2021.03.21.21253418","DOI":"10.1101\/2021.03.21.21253418"},{"key":"5365_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.615280","author":"PC Resende","year":"2020","unstructured":"Resende PC, Delatorre E, Gr\u00e4f T, Mir D, Motta FC, Appolinario LR et al (2020) Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B. 1.1. 33 during the early pandemic phase in Brazil. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.615280","journal-title":"Front Microbiol"},{"key":"5365_CR42","doi-asserted-by":"publisher","unstructured":"Lopez-Rincon A, Perez-Romero C, Tonda A, Mendoza-Maldonado L, Claassen E, Garssen J, et al (2021) Design of specific primer sets for the detection of B. 1.1. 7, B. 1.351 and P. 1 SARS-CoV-2 variants using deep learning. bioRxiv https:\/\/doi.org\/10.1101\/2021.01.20.427043","DOI":"10.1101\/2021.01.20.427043"},{"key":"5365_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.22.440932","author":"S Cherian","year":"2021","unstructured":"Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M et al (2021) Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv. https:\/\/doi.org\/10.1101\/2021.04.22.440932","journal-title":"bioRxiv"},{"key":"5365_CR44","unstructured":"Organization WH (2021) COVID-19 weekly epidemiological update, 9 May 2021"},{"key":"5365_CR45","unstructured":"Organization WH (2021) COVID-19 weekly epidemiological update, edition 42, 01 June 2021"},{"key":"5365_CR46","doi-asserted-by":"publisher","unstructured":"Ranjan R, Sharma A, Verma MK (2021) Characterization of the second wave of COVID-19 in India. medRxiv. https:\/\/doi.org\/10.1101\/2021.04.17.21255665","DOI":"10.1101\/2021.04.17.21255665"},{"key":"5365_CR47","doi-asserted-by":"crossref","unstructured":"England PH (2021) SARS-CoV-2 variants of concern and variants under investigation in England. Techn Brief 16","DOI":"10.17268\/rmt.2020.v16i01.01"},{"issue":"7858","key":"5365_CR48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","volume":"593","author":"E Volz","year":"2021","unstructured":"Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L et al (2021) Assessing transmissibility of SARS-CoV-2 lineage B117 in England. Nature 593(7858):266\u2013269","journal-title":"Nature"},{"key":"5365_CR49","unstructured":"European Centre for Disease Prevention and Control (2021) Risk related to spread of new SARS-CoV-2 variants of concern in the EU\/EEA. First update \u2013 21 January. ECDC: Stockholm"},{"key":"5365_CR50","unstructured":"WHO (2021) Weekly epidemiological update on COVID-19. 13 April 2021"},{"key":"5365_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00201-2","author":"SWX Ong","year":"2021","unstructured":"Ong SWX, Young BE, Lye DC (2021) Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00201-2","journal-title":"Lancet Infect Dis"},{"key":"5365_CR52","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1126\/science.abg3055","volume":"372","author":"NG Davies","year":"2021","unstructured":"Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD et al (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science. 372:6538","journal-title":"Science."},{"issue":"1","key":"5365_CR53","doi-asserted-by":"crossref","first-page":"2002106","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","volume":"26","author":"K Leung","year":"2021","unstructured":"Leung K, Shum MH, Leung GM, Lam TT, Wu JT (2021) Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance 26(1):2002106","journal-title":"Eurosurveillance"},{"issue":"7858","key":"5365_CR54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S et al (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593(7858):270\u2013274","journal-title":"Nature"},{"key":"5365_CR55","doi-asserted-by":"crossref","unstructured":"Schuit M, Biryukov J, Beck K, Yolitz J, Bohannon J, Weaver W, et al (2021) The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates. J Infect Dis","DOI":"10.1093\/infdis\/jiab171"},{"key":"5365_CR56","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.08.434499","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al (2021) The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. https:\/\/doi.org\/10.1101\/2021.03.08.434499","journal-title":"bioRxiv"},{"issue":"7849","key":"5365_CR57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","volume":"591","author":"BA Johnson","year":"2021","unstructured":"Johnson BA, Xie X, Bailey AL, Kalveram B, Lokugamage KG, Muruato A et al (2021) Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591(7849):293\u2013299","journal-title":"Nature"},{"key":"5365_CR58","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.17.448820","author":"A Saito","year":"2021","unstructured":"Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al (2021) SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity. bioRxiv https:\/\/doi.org\/10.1101\/2021.06.17.448820","journal-title":"bioRxiv"},{"key":"5365_CR59","unstructured":"Felipe N, Valdinete N, Victor S, Andr\u00e9 C, Fernanda N, George S, et al (2021) Nature Portfolio"},{"key":"5365_CR60","doi-asserted-by":"crossref","unstructured":"Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, et al (2021) COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P. 1.","DOI":"10.21203\/rs.3.rs-275494\/v1"},{"key":"5365_CR61","doi-asserted-by":"publisher","unstructured":"Coutinho RM, Marquitti FMD, Ferreira LS, Borges ME, da Silva RLP, Canton O, et al (2021) Model-based evaluation of transmissibility and reinfection for the P 1 variant of the SARS-CoV-2. medRxiv https:\/\/doi.org\/10.1101\/2021.03.03.21252706","DOI":"10.1101\/2021.03.03.21252706"},{"key":"5365_CR62","unstructured":"Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al (2021) Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv"},{"key":"5365_CR63","doi-asserted-by":"publisher","unstructured":"Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P (2021) Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv https:\/\/doi.org\/10.1101\/2021.01.13.426558","DOI":"10.1101\/2021.01.13.426558"},{"key":"5365_CR64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-021-01397-4","volume":"27","author":"J Singh","year":"2021","unstructured":"Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE (2021) SARS-CoV-2 variants of concern are emerging in India. Nature Med 27:1131\u20131133","journal-title":"Nature Med"},{"key":"5365_CR65","unstructured":"gov.wales. Technical Advisory Group: advice from TAG and the Chief Scientific Advisor for Health on the Delta Variant (18 June 2021). Available from: https:\/\/gov.wales\/technical-advisory-group-advice-tag-and-chief-scientific-advisor-health-delta-variant."},{"key":"5365_CR66","doi-asserted-by":"crossref","first-page":"n579","DOI":"10.1136\/bmj.n579","volume":"372","author":"R Challen","year":"2021","unstructured":"Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L (2021) Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study. BMJ. 372:n579","journal-title":"BMJ."},{"key":"5365_CR67","doi-asserted-by":"publisher","unstructured":"Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al (2021) Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv https:\/\/doi.org\/10.1101\/2021.03.07.21252647","DOI":"10.1101\/2021.03.07.21252647"},{"key":"5365_CR68","doi-asserted-by":"publisher","unstructured":"McCallum M, Bassi J, Marco A, Chen A, Walls AC, Iulio JD, et al (2021) SARS-CoV-2 immune evasion by variant B1427\/B1429. bioRxiv. https:\/\/doi.org\/10.1101\/2021.03.31.437925","DOI":"10.1101\/2021.03.31.437925"},{"key":"5365_CR69","doi-asserted-by":"publisher","unstructured":"Ferreira I, Datir R, Papa G, Kemp S, Meng B, Rakshit P, et al (2021) SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. bioRxiv https:\/\/doi.org\/10.1101\/2021.05.08.443253","DOI":"10.1101\/2021.05.08.443253"},{"key":"5365_CR70","doi-asserted-by":"publisher","unstructured":"Yadav PD, Mohandas S, Shete AM, Nyayanit DA, Gupta N, Patil DY, et al (2021) SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. bioRxiv. https:\/\/doi.org\/10.1101\/2021.05.05.442760","DOI":"10.1101\/2021.05.05.442760"},{"key":"5365_CR71","unstructured":"Control ECfDPa. Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU\/EEA. ECDC: Stockholm. 11 May 2021"},{"key":"5365_CR72","doi-asserted-by":"publisher","unstructured":"Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al (2021) Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv https:\/\/doi.org\/10.1101\/2021.01.26.21250224","DOI":"10.1101\/2021.01.26.21250224"},{"issue":"11","key":"5365_CR73","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","volume":"26","author":"AWD Edridge","year":"2020","unstructured":"Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K et al (2020) Seasonal coronavirus protective immunity is short-lasting. Nat Med 26(11):1691\u20131693","journal-title":"Nat Med"},{"key":"5365_CR74","doi-asserted-by":"publisher","unstructured":"Aldridge R, Lewer D, Beale S, Johnson A, Zambon M, Hayward A, et al (2020) Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study [version 2; peer review: 2 approved]. Welcome Open Res https:\/\/doi.org\/10.12688\/wellcomeopenres.15812.2","DOI":"10.12688\/wellcomeopenres.15812.2"},{"issue":"6534","key":"5365_CR75","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.abf6950","volume":"371","author":"KR McCarthy","year":"2021","unstructured":"McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G et al (2021) Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science 371(6534):1139\u20131142","journal-title":"Science"},{"issue":"2","key":"5365_CR76","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J et al (2021) COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184(2):476\u201388.e11","journal-title":"Cell"},{"key":"5365_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al (2021) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.03.013","journal-title":"Cell"},{"issue":"4","key":"5365_CR78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","volume":"29","author":"X Shen","year":"2021","unstructured":"Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J et al (2021) SARS-CoV-2 variant B117 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29(4):529\u2013539","journal-title":"Cell Host Microbe"},{"issue":"6534","key":"5365_CR79","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","volume":"371","author":"A Muik","year":"2021","unstructured":"Muik A, Wallisch AK, S\u00e4nger B, Swanson KA, M\u00fchl J, Chen W et al (2021) Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 371(6534):1152\u20131153","journal-title":"Science."},{"key":"5365_CR80","doi-asserted-by":"publisher","unstructured":"Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al (2021) mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv https:\/\/doi.org\/10.1101\/2021.01.25.427948","DOI":"10.1101\/2021.01.25.427948"},{"key":"5365_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.036","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann M, Arora P, Gro\u00df R, Seidel A, H\u00f6rnich BF, Hahn AS et al (2021) SARS-CoV-2 variants B1351 and P1 escape from neutralizing antibodies. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.03.036","journal-title":"Cell"},{"key":"5365_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.03.009","author":"VV Edara","year":"2021","unstructured":"Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH et al (2021) Infection- and vaccine-induced antibody binding and neutralization of the B1351 SARS-CoV-2 variant. Cell Host Microbe. https:\/\/doi.org\/10.1016\/j.chom.2021.03.009","journal-title":"Cell Host Microbe"},{"key":"5365_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.037","author":"D Zhou","year":"2021","unstructured":"Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM et al (2021) Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. https:\/\/doi.org\/10.1016\/j.cell.2021.02.037","journal-title":"Cell"},{"key":"5365_CR84","doi-asserted-by":"publisher","unstructured":"Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, et al (2021) Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. https:\/\/doi.org\/10.1101\/2021.01.27.428529","DOI":"10.1101\/2021.01.27.428529"},{"key":"5365_CR85","doi-asserted-by":"publisher","unstructured":"Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al (2021) Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv https:\/\/doi.org\/10.1016\/j.chom.2021.04.007","DOI":"10.1016\/j.chom.2021.04.007"},{"issue":"4","key":"5365_CR86","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","volume":"27","author":"CK Wibmer","year":"2021","unstructured":"Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B et al (2021) SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Med 27(4):622\u2013625","journal-title":"Nature Med"},{"key":"5365_CR87","doi-asserted-by":"publisher","unstructured":"McCallum M, Bassi J, Marco AD, Chen A, Walls AC, Iulio JD, et al (2021) SARS-CoV-2 immune evasion by variant B1427\/B1429. bioRxiv https:\/\/doi.org\/10.1101\/2021.03.31.437925","DOI":"10.1101\/2021.03.31.437925"},{"key":"5365_CR88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103740","author":"X Shen","year":"2021","unstructured":"Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W et al (2021) Neutralization of SARS-CoV-2 Variants B1429 and B1351. New Engl J Med. https:\/\/doi.org\/10.1056\/NEJMc2103740","journal-title":"New Engl J Med"},{"key":"5365_CR89","doi-asserted-by":"publisher","unstructured":"Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al (2021) Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv https:\/\/doi.org\/10.1101\/2021.02.22.432189","DOI":"10.1101\/2021.02.22.432189"},{"key":"5365_CR90","doi-asserted-by":"publisher","unstructured":"Jacobson KB, Pinsky BA, Rath MEM, Wang H, Miller JA, Skhiri M, et al (2021) Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427\/B.1.429 variant among healthcare personnel at a northern California academic medical center. medRxiv. https:\/\/doi.org\/10.1101\/2021.04.14.21255431","DOI":"10.1101\/2021.04.14.21255431"},{"key":"5365_CR91","doi-asserted-by":"publisher","unstructured":"Javanmardi K, Chou C-W, Terrace CI, Annapareddy A, Kaoud TS, Guo Q, et al (2021) Rapid characterization of spike variants via mammalian cell surface display. bioRxiv. https:\/\/doi.org\/10.1101\/2021.03.30.437622.","DOI":"10.1101\/2021.03.30.437622"},{"key":"5365_CR92","doi-asserted-by":"publisher","unstructured":"Edara V-V, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. (2021) Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. https:\/\/doi.org\/10.1101\/2021.05.09.443299","DOI":"10.1101\/2021.05.09.443299"},{"key":"5365_CR93","doi-asserted-by":"publisher","unstructured":"Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. (2021) Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. bioRxiv. https:\/\/doi.org\/10.1101\/2021.04.23.441101","DOI":"10.1101\/2021.04.23.441101"},{"issue":"7844","key":"5365_CR94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/d41586-021-00268-9","volume":"590","author":"E Callaway","year":"2021","unstructured":"Callaway E, Mallapaty S (2021) Novavax offers first evidence that COVID vaccines protect people against variants. Nature 590(7844):17","journal-title":"Nature"},{"issue":"10282","key":"5365_CR95","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S et al (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 397(10282):1351\u20131362","journal-title":"Lancet."},{"key":"5365_CR96","doi-asserted-by":"publisher","unstructured":"Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. (2021) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. https:\/\/doi.org\/10.1101\/2021.06.28.21259420","DOI":"10.1101\/2021.06.28.21259420"},{"key":"5365_CR97","doi-asserted-by":"publisher","unstructured":"Lef\u00e8vre B, Tondeur L, Madec Y, Grant R, Lina B, van der Werf S, et al. (2021) Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study. medRxiv. https:\/\/doi.org\/10.1101\/2021.07.28.21261285","DOI":"10.1101\/2021.07.28.21261285"},{"issue":"9","key":"5365_CR98","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","volume":"27","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR et al (2021) mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Med 27(9):1614\u201321","journal-title":"Nature Med"},{"issue":"35","key":"5365_CR99","doi-asserted-by":"crossref","first-page":"2100793","DOI":"10.2807\/1560-7917.ES.2021.26.35.2100793","volume":"26","author":"E Sepp\u00e4l\u00e4","year":"2021","unstructured":"Sepp\u00e4l\u00e4 E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O et al (2021) Vaccine effectiveness against infection with the Delta (B 1617 2) variant, Norway, April to August 2021. Euro Surveill 26(35):2100793","journal-title":"Euro Surveill"},{"key":"5365_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101126","author":"S Gonz\u00e1lez","year":"2021","unstructured":"Gonz\u00e1lez S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Mar\u00edn L et al (2021) Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60\u201379: a retrospective cohort study in Argentina. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101126","journal-title":"EClinicalMedicine"},{"key":"5365_CR101","doi-asserted-by":"publisher","unstructured":"Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al (2021) Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv https:\/\/doi.org\/10.1101\/2021.02.25.432969","DOI":"10.1101\/2021.02.25.432969"},{"issue":"6506","key":"5365_CR102","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V et al (2020) Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369(6506):1014\u20131018","journal-title":"Science"},{"issue":"1","key":"5365_CR103","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","volume":"12","author":"M Becker","year":"2021","unstructured":"Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser PD, Pinilla YT et al (2021) Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun 12(1):3109","journal-title":"Nat Commun"},{"key":"5365_CR104","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Hofmann-Winkler H, Kr\u00fcger N, Kempf A, Nehlmeier I, Graichen L, et al. (2021) SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv. https:\/\/doi.org\/10.1101\/2021.05.04.442663","DOI":"10.1101\/2021.05.04.442663"},{"key":"5365_CR105","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.19.21249592","author":"R Rathnasinghe","year":"2021","unstructured":"Rathnasinghe R, Jangra S, Cupic A, Mart\u00ednez-Romero C, Mulder LC, Kehrer T et al (2021) The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. MedRxiv. https:\/\/doi.org\/10.1101\/2021.01.19.21249592","journal-title":"MedRxiv"},{"issue":"4","key":"5365_CR106","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR et al (2021) Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Med 27(4):620\u2013621","journal-title":"Nature Med"},{"issue":"4","key":"5365_CR107","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA et al (2021) Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 27(4):717\u2013726","journal-title":"Nat Med"},{"issue":"15","key":"5365_CR108","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE et al (2021) Serum neutralizing activity elicited by mRNA-1273 vaccine. New Engl J Med 384(15):1468\u20131470","journal-title":"New Engl J Med"},{"key":"5365_CR109","unstructured":"Resende PC, Bezerra JF, de Vasconcelos RHT, Arantes I, Appolinario L, Mendon\u00e7a AC, et al. (2021) Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. Virological 10"},{"issue":"5","key":"5365_CR110","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3201\/eid2705.210191","volume":"27","author":"CK Nonaka","year":"2021","unstructured":"Nonaka CK, Franco MM, Gr\u00e4f T, de Lorenzo Barcia CA, de \u00c1vila Mendon\u00e7a RN, de Sousa KAF et al (2021) Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis. 27(5):1522-1524","journal-title":"Emerg Infect Dis."},{"key":"5365_CR111","unstructured":"Naveca F, da Costa C, Nascimento V, Souza V, Corado A, Nascimento F, et al. (2021) SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P. 1 in Amazonas, Brazil. virological org Preprint available at: https:\/\/virological.org\/t\/sars-cov-2-reinfection-by-thenew-variant-of-concern-voc-p-1-in-amazonas-brazil\/596 Available at: https:\/\/virological.org\/t\/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil\/596"},{"issue":"1","key":"5365_CR112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN et al (2021) Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29(1):44-57.e9","journal-title":"Cell Host Microbe"},{"issue":"5","key":"5365_CR113","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","volume":"184","author":"EC Thomson","year":"2021","unstructured":"Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva FA, Wojcechowskyj JA et al (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184(5):1171\u201387.e20","journal-title":"Cell"},{"issue":"4","key":"5365_CR114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-2600(21)00075-8","volume":"9","author":"TC Williams","year":"2021","unstructured":"Williams TC, Burgers WA (2021) SARS-CoV-2 evolution and vaccines: cause for concern? Lancet Respir Med 9(4):333\u2013335","journal-title":"Lancet Respir Med"},{"key":"5365_CR115","doi-asserted-by":"publisher","unstructured":"Motozono C, Toyoda M, Zahradnik J, Ikeda T, Saito A, Tan TS, et al. (2021) An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv. https:\/\/doi.org\/10.1101\/2021.04.02.438288.","DOI":"10.1101\/2021.04.02.438288"},{"key":"5365_CR116","doi-asserted-by":"crossref","unstructured":"Geers D, Shamier MC, Bogers S, Hartog Gd, Gommers L, Nieuwkoop NN, et al. (2021) SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Sci Immunol 6(59):eabj1750","DOI":"10.1126\/sciimmunol.abj1750"},{"issue":"1","key":"5365_CR117","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-021-24377-1","volume":"12","author":"JH Jung","year":"2021","unstructured":"Jung JH, Rha M-S, Sa M, Choi HK, Jeon JH, Seok H et al (2021) SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat Commun 12(1):4043","journal-title":"Nat Commun"},{"issue":"5","key":"5365_CR118","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s12276-021-00602-1","volume":"53","author":"Y Kasuga","year":"2021","unstructured":"Kasuga Y, Zhu B, Jang K-J, Yoo J-S (2021) Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med 53(5):723\u2013736","journal-title":"Exp Mol Med"},{"key":"5365_CR119","doi-asserted-by":"crossref","unstructured":"Zhang Q, Bastard P, Liu Z, Pen JL, Moncada-Velez M, Chen J, et al. (2020)Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 370(6515):eabd4570","DOI":"10.1126\/science.abd4570"},{"issue":"7","key":"5365_CR120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S et al (2020) Presence of genetic variants among young men with severe COVID-19. JAMA 324(7):663\u2013673","journal-title":"JAMA"},{"key":"5365_CR121","doi-asserted-by":"publisher","unstructured":"Yang Z, Zhang X, Wang F, Wang P, Kuang E, Li X (2020) Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2. bioRxiv. https:\/\/doi.org\/10.1101\/2020.08.12.247767","DOI":"10.1101\/2020.08.12.247767"},{"issue":"9","key":"5365_CR122","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41423-020-0514-8","volume":"17","author":"H-w Jiang","year":"2020","unstructured":"Jiang H-w, Zhang H-n, Meng Q-f, Xie J, Li Y, Chen H et al (2020) SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol Immunol 17(9):998\u20131000","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"5365_CR123","first-page":"1","volume":"6","author":"J Mu","year":"2020","unstructured":"Mu J, Fang Y, Yang Q, Shu T, Wang A, Huang M et al (2020) SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discovery. 6(1):1\u20134","journal-title":"Cell Discovery."},{"issue":"1","key":"5365_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Zhuang M-W, Han L, Zhang J, Nan M-L, Zhan P et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I\/MDA-5 signaling. Signal Transduct Target Ther 5(1):1\u201313","journal-title":"Signal Transduct Target Ther"},{"issue":"7858","key":"5365_CR125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH (2021) (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 593(7858):270\u2013274","journal-title":"Nature."},{"issue":"12","key":"5365_CR126","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10654-020-00698-1","volume":"35","author":"AT Levin","year":"2020","unstructured":"Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G (2020) Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 35(12):1123\u20131138","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"5365_CR127","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.3390\/ijerph17124322","volume":"17","author":"L Holmes Jr","year":"2020","unstructured":"Holmes L Jr, Enwere M, Williams J, Ogundele B, Chavan P, Piccoli T et al (2020) Black-white risk differentials in COVID-19 (SARS-COV2) Transmission, mortality and case fatality in the United States: translational epidemiologic perspective and challenges. Int J Environ Res Public Health. 17(12):4322","journal-title":"Int J Environ Res Public Health."},{"key":"5365_CR128","doi-asserted-by":"publisher","unstructured":"Paredes MI, Lunn S, Famulare M, Frisbie LA, Painter I, Burstein R, et al. (2021) Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. medRxiv https:\/\/doi.org\/10.1101\/2021.09.29.21264272","DOI":"10.1101\/2021.09.29.21264272"},{"issue":"10293","key":"5365_CR129","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","volume":"397","author":"A Sheikh","year":"2021","unstructured":"Sheikh A, McMenamin J, Taylor B, Robertson C (2021) SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397(10293):2461\u20132462","journal-title":"Lancet"},{"key":"5365_CR130","unstructured":"England PH (2021) SARS-CoV-2 variants of concern and variants under investigation in England. Techn Brief"},{"key":"5365_CR131","doi-asserted-by":"crossref","unstructured":"Ong SWX, Chiew CJ, Ang LW, Mak T-M, Cui L, Toh MPH, et al (2021) Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B. 1.1. 7 (Alpha), B. 1.315 (Beta), and B. 1.617. 2 (Delta)","DOI":"10.2139\/ssrn.3861566"},{"issue":"11","key":"5365_CR132","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.2021.2294","volume":"325","author":"RP Walensky","year":"2021","unstructured":"Walensky RP, Walke HT, Fauci AS (2021) SARS-CoV-2 variants of concern in the United States\u2014Challenges and opportunities. JAMA 325(11):1037\u20131038","journal-title":"JAMA"},{"issue":"6","key":"5365_CR133","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.7150\/ijbs.59137","volume":"17","author":"S Guo","year":"2021","unstructured":"Guo S, Liu K, Zheng J (2021) The genetic variant of SARS-CoV-2: would It matter for controlling the devastating pandemic? Int J Biol Sci 17(6):1476","journal-title":"Int J Biol Sci"},{"issue":"19","key":"5365_CR134","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","volume":"384","author":"SS Abdool Karim","year":"2021","unstructured":"Abdool Karim SS, de Oliveira T (2021) New SARS-CoV-2 variants\u2014clinical, public health, and vaccine implications. New Engl J Med 384(19):1866\u20131868","journal-title":"New Engl J Med"},{"key":"5365_CR135","volume-title":"Methods for the detection and identification of SARS-CoV-2 variants, March 2021","author":"WH Organization","year":"2021","unstructured":"Organization WH (2021) Methods for the detection and identification of SARS-CoV-2 variants, March 2021. World Health Organization, Regional Office for Europe"},{"key":"5365_CR136","unstructured":"Organization WH (2021) Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 8 January 2021"},{"key":"5365_CR137","doi-asserted-by":"crossref","unstructured":"Landis J, Moorad R, Pluta LJ, Caro-Vegas C, McNamara RP, Eason AB, et al (2021) Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants. medRxiv","DOI":"10.1101\/2021.05.08.21256775"},{"key":"5365_CR138","unstructured":"Food U, Administration D (2021) Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2-Letter to Clinical Laboratory Staff and Health Care Providers.[updated 8 January 2021"},{"key":"5365_CR139","doi-asserted-by":"publisher","unstructured":"Vogels CB, Breban M, Alpert T, Petrone ME, Watkins AE, Hodcroft E, et al. (2021) PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern. medRxiv https:\/\/doi.org\/10.1101\/2021.01.28.21250486","DOI":"10.1101\/2021.01.28.21250486"},{"key":"5365_CR140","doi-asserted-by":"publisher","unstructured":"Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, et al. (2021) 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. bioRxiv https:\/\/doi.org\/10.1101\/2021.01.26.428302","DOI":"10.1101\/2021.01.26.428302"},{"key":"5365_CR141","doi-asserted-by":"publisher","unstructured":"Perchetti GA, Zhu H, Mills MG, Shrestha L, Wagner C, Bakhash SM, et al. (2021) Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B 11 7 lineage in Washington State. medRxiv https:\/\/doi.org\/10.1101\/2021.03.10.21253321","DOI":"10.1101\/2021.03.10.21253321"},{"key":"5365_CR142","doi-asserted-by":"crossref","unstructured":"Courjon J-V, Contenti J, Demonchy E, Levraut J, Barbry P, Rios G, et al. (2021) Spread of the SARS-CoV-2 UK-variant in the South East of France: impact on COVID-19 patients age, comorbidity profiles and clinical presentation, week 50 2020 to week 8 2021. medRxiv","DOI":"10.21203\/rs.3.rs-343317\/v1"},{"key":"5365_CR143","doi-asserted-by":"crossref","unstructured":"Wang H, Miller J, Verghese M, Sibai M, Solis D, Mfuh KO, et al. (2021) Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance. medRxiv","DOI":"10.1101\/2021.04.20.21255480"},{"key":"5365_CR144","doi-asserted-by":"crossref","unstructured":"Banada PP, Green R, Banik S, Chopoorian A, Streck D, Jones R, et al. (2021) A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants. medRxiv","DOI":"10.1101\/2021.03.05.21252709"},{"issue":"16","key":"5365_CR145","doi-asserted-by":"crossref","first-page":"2100348","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","volume":"26","author":"T Funk","year":"2021","unstructured":"Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M et al (2021) Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021. Euro Surveill 26(16):2100348","journal-title":"Euro Surveill"},{"key":"5365_CR146","doi-asserted-by":"crossref","unstructured":"Bodin K, Rocklov J (2021) Inherent random fluctuations in COVID-19 outbreaks may explain rapid growth of new mutated virus variants. medRxiv","DOI":"10.1101\/2021.01.07.21249353"},{"issue":"10273","key":"5365_CR147","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","volume":"397","author":"EC Sabino","year":"2021","unstructured":"Sabino EC, Buss LF, Carvalho MP, Prete CA, Crispim MA, Fraiji NA et al (2021) Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet 397(10273):452\u2013455","journal-title":"The Lancet"},{"issue":"4","key":"5365_CR148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009453","volume":"17","author":"RT Eguia","year":"2021","unstructured":"Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA et al (2021) A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 17(4):e1009453","journal-title":"PLoS Pathog."},{"key":"5365_CR149","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","volume":"9","author":"Y Weisblum","year":"2020","unstructured":"Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC et al (2020) Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 9:e61312","journal-title":"Elife."},{"key":"5365_CR150","doi-asserted-by":"crossref","unstructured":"Mullard A (2020) How COVID vaccines are being divvied up around the world. Nature","DOI":"10.1038\/d41586-020-03370-6"},{"issue":"10278","key":"5365_CR151","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D (2021) SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet 397(10278):952\u2013954","journal-title":"The Lancet"},{"key":"5365_CR152","unstructured":"Racaniello V. Is there a limit to how much the coronavirus can mutate? livescience.com, February 11, 2021."},{"issue":"13","key":"5365_CR153","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2021.3465","volume":"325","author":"JP Moore","year":"2021","unstructured":"Moore JP (2021) Approaches for optimal use of different COVID-19 vaccines: issues of viral variants and vaccine efficacy. JAMA 325(13):1251\u20131252","journal-title":"JAMA"},{"key":"5365_CR154","volume-title":"Gavin Dabrera, Christina Achison, Wendy Barclay, Neil Ferguson, Erik Volz, Nick Loman, Andrew Rambaut, Jeff Barrett Investigation of novel SARS-COV-2 variant Variant of Concern 202012\/01","author":"SH Meera Chand","year":"2020","unstructured":"Meera Chand SH (2020) Gavin Dabrera, Christina Achison, Wendy Barclay, Neil Ferguson, Erik Volz, Nick Loman, Andrew Rambaut, Jeff Barrett Investigation of novel SARS-COV-2 variant Variant of Concern 202012\/01. Public Health England, England"},{"key":"5365_CR155","unstructured":"Andrew Rambaut NL, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz (2020) Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations"},{"issue":"7","key":"5365_CR156","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/microorganisms9071542","volume":"9","author":"S Cherian","year":"2021","unstructured":"Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M et al (2021) SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms. 9(7):1542","journal-title":"Microorganisms."},{"issue":"7","key":"5365_CR157","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","volume":"29","author":"C Motozono","year":"2021","unstructured":"Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS et al (2021) SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29(7):1124\u201336.e11","journal-title":"Cell Host Microbe"},{"issue":"19","key":"5365_CR158","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.jmb.2020.07.009","volume":"432","author":"J Chen","year":"2020","unstructured":"Chen J, Wang R, Wang M, Wei G-W (2020) Mutations Strengthened SARS-CoV-2 Infectivity. J Mol Biol 432(19):5212\u20135226","journal-title":"J Mol Biol"},{"key":"5365_CR159","doi-asserted-by":"publisher","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al (2020) Evolution of antibody immunity to SARS-CoV-2. bioRxiv https:\/\/doi.org\/10.1101\/2020.11.03.367391","DOI":"10.1101\/2020.11.03.367391"},{"issue":"5","key":"5365_CR160","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3201\/eid2705.210191","volume":"27","author":"CK Nonaka","year":"2021","unstructured":"Nonaka CK, Franco MM, Gr\u00e4f T, de Lorenzo Barcia CA, de \u00c1vila Mendon\u00e7a RN, De Sousa KAF et al (2021) Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis 27(5):1522","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"5365_CR161","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY et al (2021) Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29(3):463\u201376.e6","journal-title":"Cell Host Microbe"},{"key":"5365_CR162","doi-asserted-by":"publisher","unstructured":"Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. (2020) SARS-CoV-2 escape <em>in vitro<\/em> from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. https:\/\/doi.org\/10.1101\/2020.12.28.424451","DOI":"10.1101\/2020.12.28.424451"},{"issue":"1","key":"5365_CR163","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD et al (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 11(1):6013","journal-title":"Nat Commun"},{"key":"5365_CR164","doi-asserted-by":"publisher","unstructured":"Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, et al. (2020) Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. bioRxiv https:\/\/doi.org\/10.1101\/2020.08.26.268854","DOI":"10.1101\/2020.08.26.268854"},{"key":"5365_CR165","doi-asserted-by":"publisher","unstructured":"Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. (2021) Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv. https:\/\/doi.org\/10.1101\/2021.01.06.20248960.","DOI":"10.1101\/2021.01.06.20248960"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05365-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-022-05365-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05365-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T07:24:40Z","timestamp":1644823480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-022-05365-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":165,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5365"],"URL":"https:\/\/doi.org\/10.1007\/s00705-022-05365-2","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}